Maximizing the possibilities in the evolving treatment paradigm for R/R follicular lymphoma

touchCONGRESS for touchONCOLOGY Listen to Prof. Gianantonio Rosti, an expert in CML, as he reviews key data presented at the 2024 EHA Hybrid congress and the ESH-iCMLf 26th Annual John Goldman Conference, on tyrosine kinase inhibitors (TKIs) for treating chronic myeloid leukaemia (CML) in the first- and later-line settings. Prof. Rosti  is then joined by fellow experts, Prof. Susanne Saussele and Dr Carla Boquimpani, to consider the implications of these data for current and future clinical practice. Overview Data reviews with Prof. Rosti Expert panel discussions with Prof. Susanne Saussele and Dr Carla Boquimpani on the themes below Clinical themes Approved and emerging TKIs for CML in the first-line setting Approved and emerging TKIs for CML in the second- and later-line settings Potential impact of emerging data on current and future clinical practice The internationally renowned multiple myeloma expert faculty Prof. Gianantonio Rosti: Meldola, Italy Prof. Susanne Saussele: Mannheim, Germany Dr Carla Boquimpani: Rio de Janeiro, Brazil This touchPODCAST is for HCPs globally with the exclusion of the USA, the UK and Japan. This activity is funded by an independent medical education grant from Novartis. This activity is provided by touchIME.  For further information visit our website: TBC

touchCONGRESS for touchHAEMATOLOGY Listen to Prof. Gianantonio Rosti, an expert in CML, as he reviews key data presented at the 2024 EHA Hybrid congress and the ESH-iCMLf 26th Annual John Goldman Conference, on tyrosine kinase inhibitors (TKIs) for treating chronic myeloid leukaemia (CML) in the first- and later-line settings. Prof. Rosti  is then joined by fellow experts, Prof. Susanne Saussele and Dr Carla Boquimpani, to consider the implications of these data for current and future clinical practice. Overview Data reviews with Prof. Rosti Expert panel discussions with Prof. Susanne Saussele and Dr Carla Boquimpani on the themes below Clinical themes Approved and emerging TKIs for CML in the first-line setting Approved and emerging TKIs for CML in the second- and later-line settings Potential impact of emerging data on current and future clinical practice The internationally renowned multiple myeloma expert faculty Prof. Gianantonio Rosti: Meldola, Italy Prof. Susanne Saussele: Mannheim, Germany Dr Carla Boquimpani: Rio de Janeiro, Brazil This touchPODCAST is for HCPs globally with the exclusion of the USA, the UK and Japan. This activity is funded by an independent medical education grant from Novartis. This activity is provided by touchIME.  For further information visit our website: TBC

touchMDT for touchONCOLOGY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK. This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME. For further information visit our website:  www.touchONCOLOGY.com 

touchMDT for touchONCOLOGY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK. This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME. For further information visit our website:  www.touchONCOLOGY.com 

touchMDT for touchRESPIRATORY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK. This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME. For further information visit our website:  www.touchRESPIRATORY.com 

touchMDT for touchRESPIRATORY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK. This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME. For further information visit our website:  www.touchRESPIRATORY.com 

touchFOCUS for touchONCOLOGY Listen to Dr Jennifer Carlisle, an expert in lung cancer, as she answers a series of questions on the targeted perioperative treatment strategies and best practices for patients with resectable and unresectable early-stage EGFR-mutant NSCLC. She also discusses how the evolving treatment landscape impacts biomarker testing and the importance of multidisciplinary care for optimizing outcomes in these patients. The expert Dr Jennifer Carlisle, Winship Cancer Institute of Emory University, Atlanta, GA, USA This touchPODCAST is for HCPs only. This activity is funded by an independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: www.touchoncology.org/EGFR-mutant-treatment-options-early-NSCLC 

touchCONGRESS for touchONCOLOGY Listen to multiple myeloma expert Prof. María-Victoria Mateos review key data for BCMA-targeting agents in the treatment of multiple myeloma presented at the international Controversies in Multiple Myeloma (COMy) and European Hematology Association (EHA) 2024 congresses. Prof. Mateos is then joined by fellow experts Dr Rakesh Popat and Prof. Evangelos Terpos to discuss how these data may apply in clinical practice. Overview       Data reviews with Prof. Mateos,       Expert panel discussions with Prof. Mateos, Dr Popat and Prof. Terpos on the themes below Clinical themes Approved indications for BCMA-targeting agents, New approaches to the use of existing BCMA-targeting agents, Emerging BCMA-targeting agents The internationally renowned multiple myeloma expert faculty       Prof. María-Victoria Mateos: Salamanca, Spain,       Dr Rakesh Popat: London, UK,       Prof. Evangelos Terpos: Athens, Greece This touchPODCAST is for HCPs outside of the USA and UK only. This activity is funded by an independent medical education grant from GSK. This activity is provided by touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: https://touchoncologyime.org/bcma-mm-comy-eha-2024 

touchCONGRESS for touchHAEMATOLOGY Listen to multiple myeloma expert Prof. María-Victoria Mateos review key data for BCMA-targeting agents in the treatment of multiple myeloma presented at the international Controversies in Multiple Myeloma (COMy) and European Hematology Association (EHA) 2024 congresses. Prof. Mateos is then joined by fellow experts Dr Rakesh Popat and Prof. Evangelos Terpos to discuss how these data may apply in clinical practice. Overview       Data reviews with Prof. Mateos,       Expert panel discussions with Prof. Mateos, Dr Popat and Prof. Terpos on the themes below Clinical themes Approved indications for BCMA-targeting agents, New approaches to the use of existing BCMA-targeting agents, Emerging BCMA-targeting agents The internationally renowned multiple myeloma expert faculty       Prof. María-Victoria Mateos: Salamanca, Spain,       Dr Rakesh Popat: London, UK,       Prof. Evangelos Terpos: Athens, Greece This touchPODCAST is for HCPs outside of the USA and UK only. This activity is funded by an independent medical education grant from GSK. This activity is provided by touchIME. touchIME is an EBAC® accredited provider. For further information visit our website:  https://touchhaematologyime.org/bcma-mm-comy-eha-2024

touchEXPERT OPINIONS for touchOPHTHALMOLOGY Listen to leading experts describe the pathophysiology of open-angle glaucoma and discuss how it is targeted by current and emerging treatment options, while providing insights on how different agents and combinations are used in practice. The experts Angelo P Tanna, MD - Northwestern University Feinberg School of Medicine, Chicago, IL, USA Courtney E Bovee, MD - Bovee Eye, Tampa Bay, FL, USA Joseph F Panarelli, MD - NYU Langone Eye Center, New York, NY, USA This touchPODCAST is for HCPs only. This activity is funded by an independent medical education grant from Alcon Vision, LLC and is jointly provided by USF Health and touchIME. For further information visit our website:  https://touchOPHTHALMOLOGY.com/